{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:47:30Z","timestamp":1767840450015,"version":"3.49.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T00:00:00Z","timestamp":1539734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100012464","name":"Kaleida Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012464","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CDC Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite high hepatitis C virus (HCV) prevalence, opioid use disorder (OUD) patients on methadone rarely engage in HCV treatment. We investigated the effectiveness of HCV management via telemedicine in an opioid substitution therapy (OST) program.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>OUD patients on methadone underwent biweekly telemedicine sessions between a hepatologist and physician assistant during the entire HCV treatment course. All pretreatment labs (HCV RNA, genotype, and noninvasive fibrosis assessments) were obtained onsite and direct-acting antivirals were coadministered with methadone using modified directly observed therapy. We used multiple correspondence analysis, least absolute shrinkage and selection operator, and logistic regression to identify variables associated with pursuit of HCV care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixty-two HCV RNA\u2013positive patients (24% human immunodeficiency virus [HIV] infected, 61% male, 61% African American, 25.8% Hispanic) were evaluated. All patients were stabilized on methadone and all except 4 were HCV genotype 1 infected. Advanced fibrosis\/cirrhosis was present in 34.5% of patients. Of the 45 treated patients, 42 (93.3%) achieved viral eradication. Of 17 evaluated patients who were not treated, 5 were discontinued from the drug treatment program or did not follow up after the evaluation, 2 had HIV adherence issues, and 10 had insurance authorization issues. Marriage and a mental health diagnosis other than depression were the strongest positive predictors of treatment pursuit, whereas being divorced, separated, or widowed was the strongest negative predictor.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>HCV management via telemedicine integrated into an OST program is a feasible model with excellent virologic effectiveness. Psychosocial and demographic variables can assist in identification of subgroups with a propensity or aversion to pursue HCV treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciy899","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T23:14:55Z","timestamp":1539299695000},"page":"323-331","source":"Crossref","is-referenced-by-count":67,"title":["Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus Management in Opioid Use Disorder Patients on Methadone"],"prefix":"10.1093","volume":"69","author":[{"given":"Andrew H","family":"Talal","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University at Buffalo, State University of New York"},{"name":"START Treatment and Recovery Centers, Brooklyn"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phyllis","family":"Andrews","sequence":"additional","affiliation":[{"name":"START Treatment and Recovery Centers, Brooklyn"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Mcleod","sequence":"additional","affiliation":[{"name":"START Treatment and Recovery Centers, Brooklyn"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University at Buffalo, State University of New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clewert","family":"Sylvester","sequence":"additional","affiliation":[{"name":"START Treatment and Recovery Centers, Brooklyn"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianthi","family":"Markatou","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University at Buffalo, State University of New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence S","family":"Brown","sequence":"additional","affiliation":[{"name":"START Treatment and Recovery Centers, Brooklyn"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,10,17]]},"reference":[{"key":"2019070201025502000_CIT0001","volume-title":"Hepatitis C fact sheet No. 164","author":"World Health Organization","year":"2017"},{"key":"2019070201025502000_CIT0002","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1478-3231.2011.02494.x","article-title":"Hepatitis C virus infection in USA: an estimate of true prevalence","volume":"31","author":"Chak","year":"2011","journal-title":"Liver Int"},{"key":"2019070201025502000_CIT0003","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/ADT.0000000000000104","article-title":"Medical and behavioral approaches to engage people who inject drugs into care for hepatitis C virus infection","volume":"16","author":"Gonzalez","year":"2017","journal-title":"Addict Disord Their Treat"},{"key":"2019070201025502000_CIT0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.mm6453a1","article-title":"Summary of notifiable infectious diseases and conditions\u2014United States, 2015","volume":"64","author":"Adams","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2019070201025502000_CIT0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.mm6253a1","article-title":"Summary of notifiable infectious diseases and conditions\u2014United States, 2013","volume":"62","author":"Adams","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2019070201025502000_CIT0006","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes","volume":"22","author":"Petruzziello","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2019070201025502000_CIT0007","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/hep.27978","article-title":"Toward a more accurate estimate of the prevalence of hepatitis C in the United States","volume":"62","author":"Edlin","year":"2015","journal-title":"Hepatology"},{"key":"2019070201025502000_CIT0008","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.3748\/wjg.v23.i20.3569","article-title":"Hepatitis C in injection drug users: it is time to treat","volume":"23","author":"Grassi","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2019070201025502000_CIT0009","doi-asserted-by":"crossref","first-page":"7846","DOI":"10.3748\/wjg.v19.i44.7846","article-title":"Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care","volume":"19","author":"Zeremski","year":"2013","journal-title":"World J Gastroenterol"},{"key":"2019070201025502000_CIT0010","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited uptake of hepatitis C treatment among injection drug users","volume":"33","author":"Mehta","year":"2008","journal-title":"J Community Health"},{"key":"2019070201025502000_CIT0011","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/M16-2887","article-title":"Toward optimal control of hepatitis C virus infection in persons with substance use disorders","volume":"166","author":"Talal","year":"2017","journal-title":"Ann Intern Med"},{"key":"2019070201025502000_CIT0012","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1377\/hlthaff.2011.0663","article-title":"The urgency of providing comprehensive and integrated treatment for substance abusers with HIV","volume":"30","author":"Volkow","year":"2011","journal-title":"Health Aff (Millwood)"},{"key":"2019070201025502000_CIT0013","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/cid\/cis1007","article-title":"Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis","volume":"56","author":"Dimova","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2019070201025502000_CIT0014","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.drugpo.2017.05.019","article-title":"Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs","volume":"47","author":"Grebely","year":"2017","journal-title":"Int J Drug Policy"},{"key":"2019070201025502000_CIT0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/ADM.0000000000000041","article-title":"Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance","volume":"8","author":"Zeremski","year":"2014","journal-title":"J Addict Med"},{"key":"2019070201025502000_CIT0016","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/ADM.0000000000000196","article-title":"Improvements in HCV-related knowledge among substance users on opioid agonist therapy after an educational intervention","volume":"10","author":"Zeremski","year":"2016","journal-title":"J Addict Med"},{"key":"2019070201025502000_CIT0017","first-page":"624","article-title":"Telemedicine-based hepatitis C virus (HCV) management for individuals on opioid agonist treatment (OAT) [abstract]","volume-title":"Hepatology","author":"Talal","year":"2017"},{"key":"2019070201025502000_CIT0018","volume-title":"Recommendations for testing, managing, and treating hepatitis C","author":"American Association for the Study of Liver Diseases\/Infectious Diseases Society of America"},{"key":"2019070201025502000_CIT0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v070.i01","article-title":"MissMDA: a package for handling missing values in multivariate data analysis","volume":"70","author":"Josse","year":"2016","journal-title":"J Stat Softw"},{"key":"2019070201025502000_CIT0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v025.i01","article-title":"FactoMineR: an R package for multivariate analysis","volume":"25","author":"L\u00ea","year":"2008","journal-title":"J Stat Softw"},{"key":"2019070201025502000_CIT0021","volume-title":"Nonlinear multivariate analysis","author":"Gifi","year":"1990"},{"key":"2019070201025502000_CIT0022","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1467-9868.2007.00607.x","article-title":"L1\u2010regularization path algorithm for generalized linear models","volume":"69","author":"Park","year":"2007","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"2019070201025502000_CIT0023","first-page":"300","article-title":"A note on the use of principal components in regression","volume":"31","author":"Jolliffe","year":"1982","journal-title":"J R Stat Soc C Appl Stat"},{"key":"2019070201025502000_CIT0024","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1093\/cid\/cit263","article-title":"Understanding barriers to hepatitis C virus care and stigmatization from a social perspective","volume":"57","author":"Treloar","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2019070201025502000_CIT0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0272-7358(92)90092-M","article-title":"Dropping out of substance abuse treatment: a clinically oriented review","volume":"12","author":"Stark","year":"1992","journal-title":"Clin Psychol Rev"},{"key":"2019070201025502000_CIT0026","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1590\/S0034-8910.2014048005130","article-title":"Non-adherence to telemedicine interventions for drug users: systematic review","volume":"48","author":"Moreira","year":"2014","journal-title":"Rev Saude Publica"},{"key":"2019070201025502000_CIT0027","first-page":"CD012021","article-title":"Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs","volume":"9","author":"Platt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2019070201025502000_CIT0028","article-title":"The effects of psychosocial services in substance abuse treatment","author":"McLellan","journal-title":"JAMA 1993; 269:1953\u20139"},{"key":"2019070201025502000_CIT0029","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrgastro.2017.106","article-title":"Direct-acting antiviral agents for HCV infection affecting people who inject drugs","volume":"14","author":"Grebely","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2019070201025502000_CIT0030","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann Intern Med"},{"key":"2019070201025502000_CIT0031","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial","volume":"3","author":"Grebely","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2019070201025502000_CIT0032","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2893.2010.01411.x","article-title":"Integrated internist\u2013addiction medicine\u2013hepatology model for hepatitis C management for individuals on methadone maintenance","volume":"19","author":"Martinez","year":"2012","journal-title":"J Viral Hepat"},{"key":"2019070201025502000_CIT0033","article-title":"Patient reaction to telemedicine for clinical management of hepatitis C virus integrated into opioid treatment programs","author":"Talal","journal-title":"Telemed J E Health"},{"key":"2019070201025502000_CIT0034","article-title":"Telehealth: mapping the evidence for patient outcomes from systematic reviews","author":"Totten","year":"2016","journal-title":"Rockville, MD: Agency for Healthcare Research and Quality"},{"key":"2019070201025502000_CIT0035","first-page":"CD002098","article-title":"Interactive telemedicine: effects on professional practice and health care outcomes","author":"Flodgren","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2019070201025502000_CIT0036","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(17)30003-X","article-title":"Syndemics and the biosocial conception of health","volume":"389","author":"Singer","year":"2017","journal-title":"Lancet"},{"key":"2019070201025502000_CIT0037","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/infdis\/jix681","article-title":"Hepatitis C virus\u2013infected patients receiving opioid substitution therapy experience improvement in patient-reported outcomes following treatment with interferon-free regimens","volume":"217","author":"Stepanova","year":"2018","journal-title":"J Infect Dis"},{"key":"2019070201025502000_CIT0038","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1093\/infdis\/jix682","article-title":"Improvements in quality of life: a new indication for treating hepatitis C virus infection in persons with substance use disorders","volume":"217","author":"Perumalswami","year":"2018","journal-title":"J Infect Dis"},{"key":"2019070201025502000_CIT0039","volume-title":"Methadone hydrocloride [package insert]","year":"2016"},{"key":"2019070201025502000_CIT0040","volume-title":"Patient-centered HCV care via telemedicine for individuals on opiate substitution therapy: a stepped wedge cluster randomized controlled trial","author":"Clinical Directors Network"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/2\/323\/28893428\/ciy899.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T16:27:51Z","timestamp":1569342471000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/69\/2\/323\/5133592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,17]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,10,17]]},"published-print":{"date-parts":[[2019,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy899","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7,15]]},"published":{"date-parts":[[2018,10,17]]}}}